Yrdc-KO Mouse
一般名
Yrdc-KO
製品ID
S-KO-20849
背景情報
C57BL/6JCya
系統ID
KOCMP-230734-Yrdc-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Yrdc-KO Mouse(カタログ番号S-KO-20849)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Yrdc-KO
系統ID
KOCMP-230734-Yrdc-B6J-VB
遺伝子名
製品ID
S-KO-20849
遺伝子別名
IRIP, ITIP
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 4
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000102628
NCBIトランスクリプトID
NM_153566
ターゲット領域
Exon 2~3
有効領域の大きさ
~1.3 kb
遺伝子研究の概要
YRDC, or yrdC N6 -threonylcarbamoltransferase domain containing protein, is an essential transfer RNA (tRNA) modification enzyme. It catalyzes the formation of N6 -threonylcarbamoyladenosine (t6A) on ANN-decoding tRNA species, which is crucial for accurate protein synthesis and is associated with pathways like translation [1,5,7,9,10]. It also interacts with the KEOPS complex, playing a role in maintaining genome integrity and telomere homeostasis [5]. Genetic models can be used to study its functions in biological processes and diseases.
Knockdown of YRDC in glioblastoma stem cells reduced t6A formation, suppressed global translation and inhibited tumor growth both in vitro and in vivo. Threonine, an essential substrate of YRDC, accumulated in these cells, facilitating t6A formation and shifting the proteome to support mitosis-related genes [1]. In hepatocarcinoma cells, YRDC knockdown decreased susceptibility to lenvatinib, and it was found to regulate the protein translation of KRAS [2]. In non-small cell lung cancer (NSCLC), knockdown of YRDC in cell lines suppressed cell growth and colony formation and induced apoptosis [3]. In hepatocellular carcinoma, YRDC depletion suppressed proliferation, migration and invasion of cells, while overexpression had the opposite effect, and it promoted progression by activating MEK/ERK signaling pathways [4]. Biallelic variants in YRDC in a patient caused a developmental disorder with progeroid features, due to impaired YRDC function, reduced t6A modifications, telomere shortening and DNA repair defects [5]. In NSCLC cells, RNA structure formation in YRDC 3' UTR can suppress ELAVL1 binding, leading to EGFR-TKI sensitivity by impairing YRDC translation [6]. In osteosarcoma, knockdown of circRBMS3, which can regulate YRDC through 'sponging' miR-424-5p, inhibited malignant phenotypes in vivo [8]. Mutations in YRDC also cause an extremely severe form of Galloway-Mowat syndrome [9].
In conclusion, YRDC is crucial for tRNA modification and accurate protein synthesis. Model-based research, especially through loss-of-function experiments, has revealed its significant roles in multiple diseases such as various cancers, developmental disorders, and Galloway-Mowat syndrome. Understanding YRDC can provide insights into disease mechanisms and potential therapeutic targets.
References:
1. Wu, Xujia, Yuan, Huairui, Wu, Qiulian, Zhang, Nu, Rich, Jeremy N. 2024. Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming. In Nature cancer, 5, 1024-1044. doi:10.1038/s43018-024-00748-7. https://pubmed.ncbi.nlm.nih.gov/38519786/
2. Guo, Jun, Zhu, Peng, Ye, Zhi, Zhou, Honghao, Li, Qing. 2021. YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS. In Frontiers in pharmacology, 12, 744578. doi:10.3389/fphar.2021.744578. https://pubmed.ncbi.nlm.nih.gov/34658879/
3. Shen, Haibo, Zheng, Enkuo, Yang, Zhenhua, Li, Rui, Zhao, Guofang. 2020. YRDC is upregulated in non-small cell lung cancer and promotes cell proliferation by decreasing cell apoptosis. In Oncology letters, 20, 43-52. doi:10.3892/ol.2020.11560. https://pubmed.ncbi.nlm.nih.gov/32565932/
4. Huang, Shiqiong, Zhu, Peng, Sun, Bao, Shu, Yan, Li, Qing. 2019. Modulation of YrdC promotes hepatocellular carcinoma progression via MEK/ERK signaling pathway. In Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 114, 108859. doi:10.1016/j.biopha.2019.108859. https://pubmed.ncbi.nlm.nih.gov/30978526/
5. Schmidt, Julia, Goergens, Jonas, Pochechueva, Tatiana, Yigit, Gökhan, Wollnik, Bernd. 2021. Biallelic variants in YRDC cause a developmental disorder with progeroid features. In Human genetics, 140, 1679-1693. doi:10.1007/s00439-021-02347-3. https://pubmed.ncbi.nlm.nih.gov/34545459/
6. Shi, Boyang, An, Ke, Wang, Yueqin, Tian, Xin, Kan, Quancheng. 2022. RNA Structural Dynamics Modulate EGFR-TKI Resistance Through Controlling YRDC Translation in NSCLC Cells. In Genomics, proteomics & bioinformatics, 21, 850-865. doi:10.1016/j.gpb.2022.10.006. https://pubmed.ncbi.nlm.nih.gov/36435452/
7. Harris, Kimberly A, Jones, Victoria, Bilbille, Yann, Swairjo, Manal A, Agris, Paul F. 2011. YrdC exhibits properties expected of a subunit for a tRNA threonylcarbamoyl transferase. In RNA (New York, N.Y.), 17, 1678-87. doi:10.1261/rna.2592411. https://pubmed.ncbi.nlm.nih.gov/21775474/
8. Gong, Zhe, Shen, Panyang, Wang, Haitao, Fang, Xiangqian, Liu, Gang. 2023. A novel circular RNA circRBMS3 regulates proliferation and metastasis of osteosarcoma by targeting miR-424-eIF4B/YRDC axis. In Aging, 15, 1564-1590. doi:10.18632/aging.204567. https://pubmed.ncbi.nlm.nih.gov/36897170/
9. Arrondel, Christelle, Missoury, Sophia, Snoek, Rozemarijn, van Tilbeurgh, Herman, Mollet, Géraldine. 2019. Defects in t6A tRNA modification due to GON7 and YRDC mutations lead to Galloway-Mowat syndrome. In Nature communications, 10, 3967. doi:10.1038/s41467-019-11951-x. https://pubmed.ncbi.nlm.nih.gov/31481669/
10. El Yacoubi, Basma, Lyons, Benjamin, Cruz, Yulien, Swairjo, Manal A, de Crécy-Lagard, Valérie. 2009. The universal YrdC/Sua5 family is required for the formation of threonylcarbamoyladenosine in tRNA. In Nucleic acids research, 37, 2894-909. doi:10.1093/nar/gkp152. https://pubmed.ncbi.nlm.nih.gov/19287007/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
